A CrossMab-based bispecific antibody, A2V, simultaneously inhibits VEGF- and Ang-2-dependent signaling to extinguish aberrant vessel formation and interrupt resistance feedback at its source, thereby achieving more comprehensive control of the tumor's "vascular ecology" 52. The gene discussed is ANGPT2; the disease is neoplasm.